HSS J. 2010 Sep;6(2):182-9. doi: 10.1007/s11420-010-9171-2. Epub 2010 Jul 27.
Cardiovascular disease is prevalent in patients undergoing orthopedic surgery. Many patients who have undergone previous percutaneous coronary intervention (PCI) with stenting are on dual antiplatelet therapy in order to minimize the risk of stent thrombosis. The optimal management of these patients in the perioperative setting remains unclear. We aim to provide information about the management of patients who have undergone a PCI with stents who are subsequently indicated for an orthopedic procedure. We will review the concerns from a cardiologist's and orthopedic surgeon's perspective in regards to the management of these patients in the perioperative setting. In addition, the current American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, and American College of Surgeons guidelines are reviewed. The decision to discontinue dual antiplatelet therapy in a patient who has undergone a PCI with stent should be made only after careful review of the risks for thrombosis and bleeding. Best practice suggests that these risks should be jointly assessed by the orthopedic surgeon and cardiologist. Those patients with stents at high risk of thrombosis should have surgery delayed if possible. There is little data supporting a significantly increased bleeding risk associated with mortality in orthopedic patients when antiplatelet therapy is continued perioperatively.
心血管疾病在接受骨科手术的患者中很常见。许多先前接受过经皮冠状动脉介入治疗 (PCI) 加支架植入的患者正在接受双联抗血小板治疗,以最大程度降低支架血栓形成的风险。这些患者在围手术期的最佳管理仍不清楚。我们旨在提供有关已接受 PCI 加支架植入术且随后需要进行骨科手术的患者的管理信息。我们将从心脏病专家和骨科医生的角度来探讨这些患者在围手术期的管理问题。此外,还回顾了当前美国心脏协会、美国心脏病学会、心血管造影和介入学会以及美国外科医师学会的指南。只有在仔细评估血栓形成和出血风险后,才能决定停止接受 PCI 加支架植入术的患者的双联抗血小板治疗。最佳实践建议,应由骨科医生和心脏病专家共同评估这些风险。如果可能的话,应延迟对高血栓形成风险支架的患者进行手术。继续进行围手术期抗血小板治疗与骨科患者的死亡率相关的出血风险增加几乎没有数据支持。